

1.	<p>Treatment & Condition</p> <p>Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma.</p>
2.	<p>Associated appraisal body & Summary of ruling</p> <p>NICE Technology Appraisal guidance TA446 (June 2017)</p> <p>Brentuximab vedotin is recommended as an option for treating CD30-positive Hodgkin lymphoma in adults, only if:</p> <ul style="list-style-type: none"> • they have relapsed or refractory disease after autologous stem cell transplant and • the company provides brentuximab vedotin at the price agreed with NHS England in the commercial access agreement. <p>Note: This guidance also contains further recommendation on the use of brentuximab vedotin within the Cancer Drugs Fund as an option for treating CD30-positive Hodgkin lymphoma. This does not apply in Northern Ireland.</p>
3.	<p>Number of people in Northern Ireland expected to take up service/therapy (including new cases per year)</p> <p>Patient numbers in Northern Ireland are anticipated to be in the region of 5-7 patients per annum.</p>
4.	<p>Patient Access Scheme Availability</p> <p>(Yes/No)</p> <p>The pricing arrangement considered during guidance development was one in which the company (Takeda) had agreed a patient access scheme with the Department of Health. This scheme would have provided a simple discount to the list price of brentuximab vedotin with the discount applied at the point of purchase or invoice.</p>
5.	<p>Costs (before PAS if applicable)</p>
5.1	<p>Drug cost per patient per annum (for new and prevalent cases)</p> <p>The recommended dose of brentuximab vedotin for this indication is 1.8 mg/kg administered by intravenous infusion over 30 minutes every 3 weeks.</p> <p>The list price of brentuximab vedotin is £2,500 for a 50mg vial.</p> <p>Assuming no vial sharing, the cost per patient per dose at the list price (assuming an average body weight of 73.1kg) is:</p> <p>1.8 x 73.1 = 131.85mg per dose 3 x 50mg vials per dose = 3 x £2,500 = £7,500 per dose</p>

	<p>Patients receive between 4 and 16 doses. Therefore the cost per patient is estimated to be between £30k and £120k.</p>
5.2	<p>Infrastructure costs Per annum</p> <p>Any additional infrastructure costs associated with the introduction of new cancer therapies will be dealt with as part of the routine commissioning process.</p>
6.	<p>Expected implementation period</p> <p>There is no impediment to immediate implementation for new patients.</p>
7.	<p>Commissioning arrangements</p> <p>This regimen will be formally commissioned by the HSCB/PHA via the Specialist Services Commissioning Team initially on a cost-per-case (CPC) basis for a period of 12 months. After this time, numbers of patients who received or are receiving treatment will be reviewed and consideration will be given to moving to recurrent funding to support this regimen.</p>
8.	<p>Monitoring arrangements</p> <p>The HSCB cost per case process will generate quarterly reports on the number of applications.</p> <p>HSCB currently routinely reviews quarterly monitoring information in relation to the usage of all recurrently funded specialist cancer drugs across both the Cancer Centre and other Units.</p> <p>The monitoring pro forma will be adapted to capture information in respect of this regimen and this group of patients. This monitoring report is submitted to the Specialist Services Commissioning Team for formal review and comment by the Team.</p>
9.	<p>DoH (NI) Legislative/Policy Caveats</p> <p>This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.</p> <p>Recommendation 1.2 of the NICE TA recommends brentuximab vedotin for use within the Cancer Drugs Fund as an option for treating CD30-positive Hodgkin lymphoma. This does not apply in Northern Ireland.</p>